A1 Journal article – refereed
Anticoagulation, CHA(2)DS(2)VASc Score, and Thromboembolic Risk of Cardioversion of Acute Atrial Fibrillation (from the FinCV Study)

List of Authors: Toni Grönberg, Juha E. K. Hartikainen, Ilpo Nuotio, Fausto Biancari, Antti Ylitalo, K. E. Juhani Airaksinen
Publication year: 2016
Journal: American Journal of Cardiology
Journal acronym: AM J CARDIOL
Volume number: 117
Issue number: 8
ISSN: 0002-9149
eISSN: 1879-1913

The efficacy of the anticoagulation in preventing thromboembolic complications (TEC) and the usefulness of the CHA(2)DS(2)VASc score for assessing stroke risk during cardioversion of acute atrial fibrillation (AF) are unclear. Thus, our objectives were to assess the ability of the CHA(2)DS(2)VASc score to predict TEC and to evaluate the efficacy of anticoagulation in the prevention of TEC in Finnish CardioVersion (FinCV) study. The FinCV is a retrospective, multicenter study of 3,143 patients, who underwent 7,660 cardioversions for acute AF. The value of the CHA(2)DS(2)VASc score in predicting TEC was analyzed separately in cardioversions performed without, and with anticoagulation. A total of 40 definite TEC (0.6%) occurred after 7,237 successful cardioversions and 1 stroke (0.2%) after 423 unsuccessful procedures. In 5,362 cardioversions performed without anticoagulation, the risk of definite TEC increased significantly from 0.4% in patients with a CHA(2)DS(2)VASc score of 0 to 1 to 2.3% in those with score of >= 5 (p <0.001 for trend). The C-statistic of the CHA(2)DS(2)VASc score was 0.72 (0.61 to 0.83) in predicting definite TEC in non-anticoagulated patients with first cardioyersion. The incidence of definite TEC was significantly lower in 2,298 cardioversions performed during anticoagulation (0.1% vs 0.7%, p = 0.001), and the preventive effect of anticoagulation was significant in patients with a score of >= 2 (0.2% vs 1.1%, p = 0.001). In conclusion, CHA(2)DS(2)VASc score is a strong predictor of TEC in cardioversion of acute AF performed without anticoagulation. Importantly, periprocedural anticoagulation reduced the risk of TEC by 82%. The overall risk of these complications was low after failed cardioversion. (C) 2016 Elsevier Inc. All rights reserved.

Last updated on 2019-20-07 at 17:23